Rick Gonzalez's departure as Chief Commercial Officer of Celularity Inc was reported; the filing names no successor. As of November 6, 2026, Celularity Inc has reported 7 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 21, 2026 to September 29, 2026, naming 8 appointments and 2 departures (Form 8-K, August 7, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Celularity Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Naveen Jain · Role: Director · 8-K, 2026-09-29
- · In / out: In · Person: Philip A. Barach · Role: Director · Effective: 2026-09-24 · 8-K, 2026-09-28
- · In / out: Out · Person: Rick Gonzalez · Role: Chief Commercial Officer · 8-K, 2026-08-07
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-30
- · In / out: In · Person: Steven N. Gordon · Role: Chief Operating and Administrative Officer · 8-K, 2026-06-25
Celularity Inc reported changes in 7 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-21 to 2026-09-29. They name 6 people, with 8 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Celularity Inc files it.
Also on the record for Celularity Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 28, 2026 | Stake report, Schedule 13D/A, by PHILIP & DANIELE BARACH FAMILY TRUST | 29% of the class | 5%+ stakes | Source |
| June 23, 2026 | Stake report, Schedule 13D/A, by PHILIP & DANIELE BARACH FAMILY TRUST | 15.8% of the class | 5%+ stakes | Source |
| April 22, 2026 | Stake report, Schedule 13D/A, by PHILIP & DANIELE BARACH FAMILY TRUST | 20.1% of the class | 5%+ stakes | Source |
| April 3, 2026 | Stake report, Schedule 13D, by PHILP & DANIELE BARACH FAMILY TRUST | 9.56% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Lincoln Alternative Strategies LLC | — | 5%+ stakes | Source |
| November 3, 2025 | Form D, private offering | $2M sold | Form D page | Source |
| August 27, 2025 | Stake report, Schedule 13G, by Lincoln Alternative Strategies LLC | 5.14% of the class | 5%+ stakes | Source |
| August 5, 2025 | Form D, private offering | $1.03M sold | Form D page | Source |
| August 5, 2025 | Form D, private offering | $6.81M sold | Form D page | Source |
| August 5, 2025 | Form D, private offering | $2M sold | Form D page | Source |
| July 28, 2025 | Stake report, Schedule 13D/A, by Dragasac Limited | 41% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Celularity Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Celularity Inc and the records around it.
Celularity Inc elsewhere on the record
- 5%+ stake filings Sep 2026
- Form D filing Nov 2025
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026), Bionano Genomics, Inc. (Sep 2025)
Watch Celularity Inc
Get an email when Celularity Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Celularity Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Celularity Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Celularity Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-29 | In | Director | 8-K, 2026-09-29 | ||
| 2026-09-29 | In | 8-K, 2026-09-29 | |||
| 2026-09-29 | Out | 8-K, 2026-09-29 | |||
| 2026-09-28 | In | Director | 2026-09-24 | 8-K, 2026-09-28 | |
| 2026-09-28 | In | 8-K, 2026-09-28 | |||
| 2026-08-07 | Out | Chief Commercial Officer | 8-K, 2026-08-07 | ||
| 2026-06-30 | Reported | not named in the filing | 8-K, 2026-06-30 | ||
| 2026-06-25 | In | Chief Operating and Administrative Officer | 8-K, 2026-06-25 | ||
| 2026-06-25 | In | Chief Legal and Strategy Officer | 2026-06-19 | 8-K, 2026-06-25 | |
| 2026-06-25 | In | Director | 2026-06-19 | 8-K, 2026-06-25 | |
| 2026-06-03 | In | Chief Commercial Officer | 8-K, 2026-06-03 | ||
| 2026-04-21 | Reported | not named in the filing | 8-K, 2026-04-21 |
Who leads Celularity Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Naveen Jain, appointed (filed 2026-09-29).
- Chief Commercial Officer: Rick Gonzalez, departure reported (filed 2026-08-07). No successor is named in these filings.
- Chief Operating and Administrative Officer: Steven N. Gordon, appointed (filed 2026-06-25).
- Chief Legal and Strategy Officer: K. Harold Fletcher, appointed, effective 2026-06-19 (filed 2026-06-25).
New leaders reset buying decisions — get the Full Report on Celularity Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Celularity Inc, with the record behind each one.
Find candidates like Director at Celularity IncEvery change, in the filing's words
Appointed: Naveen Jain, Director
On September 29, 2026, the Board of Directors (the "Board") of Celularity Inc. (the "Company") appointed Naveen Jain to serve as a member of the Board, with his term to commence upon the expiration of the applicable waiting period following the filing and mailing of an Information Statement pursuant to Section 14(f) of the Securities Exchange Act of 1934, as amended, and Rule 14f-1 promulgated thereunder (the "Effective Time").
Appointed: Naveen Jain
Mr. Jain was designated for appointment to the Board pursuant to the board designation rights granted to certain investors in connection with the Company's previously announced September 2026 financing.
Departing: Diane Parks
In relation to this appointment, Diane Parks notified the Company of her decision to resign from the Board, effective as of the Effective Time.
- Mr. Jain is the founder and Chief Executive Officer of Viome Life Sciences Inc., a health technology company that applies artificial intelligence and molecular data to personalized health and nutrition.
- Mr. Jain previously founded InfoSpace, Intelius and TalentWise and is the founder of Moon Express.
- Mr. Jain will participate in the Company's standard compensation arrangements for non-employee directors and is expected to enter into the Company's standard form of indemnification agreement for directors and officers.
- Mr. Jain has not initially been appointed to any committee of the Board.
- Ms. Parks' decision to resign was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- On September 29, 2026, the Company issued a press release announcing Mr. Jain's appointment to the Board.
Appointed: Philip A. Barach, Director, effective 2026-09-24
Effective September 24, 2026, the Board appointed Philip A. Barach to serve as a director of the Company.
Appointed: Philip A. Barach
Mr. Barach was appointed pursuant to the Board Rights Agreement described under
- Effective September 24, 2026, Geoffrey Ling, M.D., Ph.D. resigned from the Board.
- Dr. Ling's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Departing: Rick Gonzalez, Chief Commercial Officer
As of such date, Mr. Gonzalez ceased serving as the Company's Chief Commercial Officer.
- On August 5, 2026, Celularity Inc. (the "Company") terminated the employment of Rick Gonzalez, the Company's Chief Commercial Officer, effective immediately.
Reported
Effective June 26, 2026, Vincent LeVien resigned as a member of the Company's Board of Directors.
- Mr. LeVien's resignation was not the result of any disagreement with the Company relating to the Company's operations, policies or practices.
Appointed: Steven N. Gordon, Chief Operating and Administrative Officer
On June 19, 2026, the Company's Board of Directors (the "Board") appointed Steven N. Gordon, Esq. as the Company's Chief Operating and Administrative Officer.
Appointed: K. Harold Fletcher, Chief Legal and Strategy Officer, effective 2026-06-19
Effective June 19, 2026, the Board also appointed K. Harold Fletcher, Esq. as the Company's Chief Legal and Strategy Officer and Corporate Secretary.
Appointed: Steven N. Gordon, Director, effective 2026-06-19
Effective June 19, 2026, the Board appointed Mr. Gordon as a member of the Board.
- Mr. Gordon is an entrepreneur, investor and business executive with significant experience in corporate finance, operations, strategic development and capital formation in the biotechnology sector.
- Mr. Gordon has been actively involved in the Company's financing, restructuring and strategic initiatives and has served as the Company's EVP, Business Affairs since January 2026.
- Mr. Fletcher has substantial experience in corporate governance, securities law, strategic transactions, financings, healthcare compliance and public company matters.
- Prior to his appointment, Mr. Fletcher served as the Company's EVP, Legal and Strategy since January 2026 and previously served as the Company's General Counsel, Chief Compliance Officer and Assistant Corporate Secretary.
- Any compensation arrangements for Mr. Gordon and Mr. Fletcher will be disclosed, if required, in subsequent filings.
- Mr. Gordon will serve as a director until his successor is duly elected and qualified or until his earlier resignation, death or removal.
Appointed: Rick Gonzalez, Chief Commercial Officer
On May 29, 2026, Celularity Inc. ("Celularity") appointed Rick Gonzalez as Chief Commercial Officer of Celularity.
- Mr. Gonzalez will report directly to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman and Chief Executive Officer.
- Celularity has not entered into a definitive employment agreement with Mr. Gonzalez in connection with his appointment.
- Celularity will disclose the material terms of any definitive compensatory arrangement with Mr. Gonzalez in a subsequent filing with the Securities and Exchange Commission, as required.
Reported
On April 15, 2026, Stephen A. Brigido, the Company's President, Degenerative Diseases, resigned from his position, effective immediatly.
- In April 2026, the Company implemented certain organizational changes in connection with its ongoing strategic realignment and previously announced divestiture of its biomaterials business to NexGel.
- On April 9, 2026, the Company terminated the employment of John R. Haines, the Company's Senior Vice President, Global Manager and Chief Administrative Officer, without cause.
- Mr. Haines' final day of employment is expected to be May 8, 2026.
Tools for this story
Each opens in a new tab, filled in for Celularity Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.